Antibiotic resistance is one of the most urgent public health challenges of our time — and the research community is fighting back. During April 2026, , Fedora Pharmaceuticals presented a comprehensive body of preclinical data on its lead candidate, FPI-2119, at ESCMID Global 2026 in Munich, Germany (April 17–21). With eight poster presentations, the breadth of evidence on display reflects the enormous potential of FPI-2119 to become a transformative new tool in the fight aga

Potent antibacterial activity against Gram-negative community and hospital-acquired infections highlighted across eight posters and two presentations April 19, 2026 08:00 ET | Source: Fedora Pharmaceuticals, Inc. EDMONTON, Alberta, April 19, 2026 (GLOBE NEWSWIRE) Fedora Pharmaceuticals, Inc., a leader in the development of drugs to treat antibiotic-resistant infections, is presenting a full suite of preclinical findings from the company’s lead candidate, FPI-2119 at the Euro

April 09, 2026 08:30 ET | Source: Fedora Pharmaceuticals, Inc. EDMONTON, Alberta , April 09, 2026 (GLOBENEWSWIRE) Fedora Pharmaceuticals, Inc., a leader in the development of drugs to treat antibiotic-resistant infections, intends to present a full suite of preclinical findings from the company’s lead candidate, FPI-2119 at the upcoming European Society of Clinical Microbiology and Infectious Diseases Congress (ESCMID) congress in Munich, Germany. “The preclinical results we

By Gina Shaw Original Source: FPI-2119 investigational antibiotic A novel antibiotic that targets penicillin-binding proteins (PBPs) without relying on a beta-lactam scaffold demonstrated broad in-vitro activity, bactericidal effects, low resistance selection, and encouraging in-vivo efficacy across a series of preclinical studies presented at the inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation, in Las Vegas, on Jan. 29, 2026. Across four relat